Our fibrosis portfolio

Our fibrosis portfolio
CSR report

We are building a fibrosis portfolio with different modes of action, with an initial focus on IPF and aim to expand to other forms of organ and skin fibrosis. To this end, we are currently working on a number of drug candidates with distinct novel mechanisms of action, which are fully proprietary to us. In IPF, we believe that having multiple mechanisms of action within our own portfolio of candidates allows the exploration of combinations of therapies. Last year we expanded clinical research into SSc, and we plan to explore additional fibrotic indications with our earlier stage compounds. At the time of publication of this report, it was decided to temporarily pause the start of Phase 1 studies, given de COVID-19 pandemic.

Our IPF portfolio and expected clinical development in 2020:

Building an IPF & fibrosis portfolio

Two toplines in H2 ’20, ISABELA futility in Q1 ‘21

Building an IPF & fibrosis portfolio (graphic)